LMH Biotech Sdn. Bhd. is a Malaysian contract research organization, manufacturer, and medical device distributor with exclusive rights to the manufacturing and regional distribution of Intralink-Spine’s revolutionary treatment for spinal disc degeneration and chronic low back pain – GENTIS (previously the Réjuve System).
GENTIS is an injectable “nano-tethering” polymeric medical device implanted via a standard image-guided injection. This micro-invasive procedure can be performed on an outpatient basis and typically involves just one injection treatment.
The key to GENTIS’ effectiveness is its ability to add a large number of load-supporting polymers to the damaged collagen matrix of a degraded spinal disc. By these implanted polymers, GENTIS mechanically strengthens the disc tissue and stabilizes the spinal joint thereby addressing chronic back pain at its source.
LMH Biotech is privately held, primarily by Malaysian investors. The company has successfully manufactured GENTIS and conducted a small clinical trial in Kuala Lumpur. The company now awaits CE Marking for GENTIS at which point it will register and distribute the product in Malaysia and other Southeast Asian Countries.